Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know

The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.